Medical Excellence Capital — Full Portfolio

Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.

BiotechDeep TechMedical DevicesBlue Bell, US

Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in

Co-investorsSmartGateVC

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsForesite CapitalDeerfield Management Company

Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins.

BiotechDeep TechMedical DevicesBlue Bell, US

Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in

Co-investorsSmartGateVC

BiotechNew York, US

Andrea Spezzi(Executive Officer, Director)

BoardJohn Prufeta(Director)in

Board seatEric Heil· per SEC Form D · $5M raise · filed Sep 2022

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical Devices

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)

Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+3 more

Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.

BiotechWaltham, US

THERESA CAMERON(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)

Co-investorsAstellas Venture Management LLCRA CapitalSanofi VenturesOpenSky Ventures

Company developing oral small-molecule CLIC1 inhibitors to treat obesity and metabolic diseases through hunger-pathway modulation.

ClicBio develops oral small-molecule CLIC1 inhibitors to treat metabolic diseases by modulating appetite through hypothalamic neuron regulation.

BiotechDeep TechHealthtech

John Dobak(CEO and Co-Founder)Jay Hagan(Board Member and Co-Founder)Bruce Steel(Board Member and Co-Founder)Olivia Osborn(Co-Founder/Advisor)

GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.

AI & Machine LearningBiotechMedical DevicesCambridge, US

George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)Alex Ng(Chief Innovation Officer & Co-Founder)

Co-investorsAndreessen HorowitzGlobal BrainHumboldt

Precision immunotherapy company using single-cell genomics and machine learning to develop novel cancer treatments, with lead programs in clinical development.

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLaura Brass(Director)inKai Wucherpfennig(Director)

Co-investorsDC Investment PartnersLongwood FundNovartis Venture FundOno Venture Investment, Inc.Solasta VenturesAgent Capital+2 more

Biotech company developing Spiroligomer™ molecules as a new class of targeted therapeutic medicines for diagnostic and therapeutic applications.

Spinout from Children's Hospital of Philadelphia using AI and machine learning to develop therapies for genetic diseases in children.

Nobias Therapeutics is a clinical-stage drug developer creating small-molecule therapeutics for genetically-defined rare diseases, initially focused on pediatric indications with potential expansion into adult and non-rare conditions.

AI & Machine LearningBiotechHealthtech

Hakon Hakonarson(Co-Founder and Chief Scientific Advisor)Brian Halak(Co-Founder)Patrick Dougherty(Chief Executive Officer)Ryan McMillian(Consulting Chief Financial Officer)

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechHealthtechSouth San Francisco, US

Kenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesVivo CapitalARCH Venture Partners+1 more

San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.

Co-investorsARCH Venture PartnersLightstone Ventures

Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.

BiotechDigital HealthMedical DevicesSan Diego, US

Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)

Co-investorsDns CapitalGreatPoint VenturesWittington VenturesDomain AssociatesOS Fund

TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform.

BiotechHealthtechSan Carlos, US

Caitlyn Miller(CEO & Co-Founder)Jennifer Cochran(Co-Founder)Carolyn Bertozzi(Co-Founder)Ronald Levy(Co-Founder)

BoardOmri Amirav-Drory(Director)inJohn Prufeta(Director)in

Co-investors2048 VenturesFifty YearsNFX